Cardax, Inc. (CDXI) Research

Cardax, Inc. is a biopharmaceutical enterprise focused on both creating and marketing nutritional supplements for maintaining inflammatory well-being, as well as developing pharmaceutical treatments for chronic ailments rooted in inflammation and oxidative stress. Its product portfolio includes ZanthoSyn, an advanced supplement for inflammation, health, and longevity that delivers astaxanthin with superior absorption and purity. This product is primarily distributed through online sales and wholesale channels. The company is also progressing two pharmaceutical candidates: CDX-101, an astaxanthin-derived drug candidate intended to address cardiovascular inflammation and dyslipidemia, with a primary focus on severe hypertriglyceridemia; and CDX-301, a zeaxanthin-based pharmaceutical currently under development for macular degeneration. Cardax, Inc. maintains its headquarters in Honolulu, Hawaii.

Market snapshot

Symbol
CDXI
Price
$0.00
Day change
0.00%
Market cap
$80.0
P/E ratio
-0.00x
52-week range
0.000001-0.004
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Eloxx Pharmaceuticals, Inc. (ELOX)
  • Cannabiz Mobile, Inc. (LGBI)
  • MedAvail Holdings, Inc. (MDVLQ)
  • Micron Solutions, Inc. (MICRD)
  • Modern Technology Corp. (MODC)
  • MetaStat, Inc. (MTST)
  • Nabriva Therapeutics plc (NBRVF)
  • NexImmune, Inc. (NEXI)

Recent insider activity

  • PAULSON CAPITAL (DELAWARE) CORP. — P-Purchase (500000 shares) on 2014-02-24
  • Paulson Cardax Investments 1 LLC — P-Purchase (500000 shares) on 2014-02-24
  • Paulson Cardax Investments 1 LLC — J-Other (1068477 shares) on 2014-02-07
  • PAULSON CAPITAL (DELAWARE) CORP. — J-Other (1068477 shares) on 2014-02-07
  • PAULSON CAPITAL (DELAWARE) CORP. — trade (0 shares) on 2014-02-07

Open Cardax, Inc. (CDXI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.